GO:0004122 cystathionine beta-synthase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004122 cystathionine beta-synthase activity describes the catalysis of L-serine and L-homocysteine to cystathionine and water, a central reaction in the transsulfuration pathway.
• The enzyme cystathionine beta-synthase (CBS) is a pyridoxal 5'-phosphate (PLP)-dependent enzyme that also requires heme for regulation and is activated by S-adenosylmethionine (SAM).
• Loss-of-function mutations in CBS cause classical homocystinuria, an inherited metabolic disorder with elevated homocysteine and multi-organ complications.
• CBS activity is allosterically regulated by SAM through its C-terminal regulatory domain, and disease-causing linker mutations impair this regulation.
• CBS expression and activity vary across cell types, including human leukemia cell lines, and are implicated in cancer and neuropsychiatric conditions.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise interrogation of CBS function in disease and metabolism.
Description
Cystathionine beta-synthase (CBS) activity, annotated as GO:0004122, is a molecular function that catalyzes the condensation of L-serine and L-homocysteine to form cystathionine and water. This reaction is the first and rate-limiting step of the transsulfuration pathway, which converts homocysteine to cysteine and links methionine metabolism to glutathione synthesis and sulfur-containing biomolecules. Because homocysteine is a toxic intermediate, its efficient removal by CBS is critical for cellular and organismal health. Researchers study GO:0004122 to understand sulfur amino acid metabolism, to dissect the molecular basis of homocystinuria, and to explore new therapeutic strategies for CBS deficiency. The enzyme is a pyridoxal 5'-phosphate (PLP)-dependent protein that also contains a heme cofactor and is allosterically activated by S-adenosylmethionine (SAM). Mutations in the CBS gene that impair its activity or regulation lead to classical homocystinuria, characterized by elevated plasma homocysteine, connective tissue defects, and thromboembolism. Beyond inherited disease, CBS activity has been linked to cancer cell metabolism, neurological function, and colonic motility, making it a target of broad biomedical interest.
cystathionine beta-synthase activity At A Glance
| GO ID | GO:0004122 |
|---|---|
| GO term | cystathionine beta-synthase activity |
| Ontology | molecular_function |
| Synonym | beta-thionase activity; L-serine hydro-lyase (adding homocysteine); methylcysteine synthase activity; serine sulfhydrase activity; serine sulfhydrylase activity |
| Major function | Catalyzes the condensation of L-serine and L-homocysteine to cystathionine and water, the first step of transsulfuration. |
| Cofactors | Pyridoxal 5'-phosphate (PLP) and heme. |
| Regulation | Allosterically activated by S-adenosylmethionine (SAM) via the C-terminal regulatory domain. |
| Pathology | Deficiency causes classical homocystinuria; dysregulation linked to cancer and neurological disorders. |
What Is GO:0004122?
GO:0004122 cystathionine beta-synthase activity is defined by the Gene Ontology as the catalysis of the reaction: L-serine + L-homocysteine = cystathionine + H2O. In other words, it is the enzymatic activity that joins serine and homocysteine to produce cystathionine, a key intermediate in the transsulfuration pathway. This activity is synonymous with beta-thionase activity, L-serine hydro-lyase (adding homocysteine), methylcysteine synthase activity, serine sulfhydrase activity, and serine sulfhydrylase activity. The reaction requires pyridoxal 5'-phosphate (PLP) as a cofactor and is allosterically regulated by S-adenosylmethionine (SAM).
Why Is cystathionine beta-synthase activity Important in Cell Biology?
Cystathionine beta-synthase activity is essential for maintaining low homocysteine levels and for the biosynthesis of cysteine, a precursor of glutathione and other sulfur-containing molecules. Its dysfunction leads to homocystinuria, a severe metabolic disorder with ocular, skeletal, vascular, and neurological manifestations. Moreover, CBS activity influences cancer cell proliferation, redox balance, and neurotransmitter metabolism, making it a potential therapeutic target. Understanding its molecular mechanism and regulation is therefore critical for developing treatments for CBS deficiency and for modulating sulfur metabolism in disease.
• Maintains homocysteine homeostasis by converting homocysteine to cystathionine.
• Provides cysteine for glutathione synthesis and antioxidant defense.
• Mutations in CBS cause classical homocystinuria, a multisystem disorder.
• Allosteric regulation by SAM links CBS activity to methionine status.
• CBS expression varies in leukemia cell lines, suggesting roles in cancer metabolism.
• Inhibition of CBS by isoflurane contributes to delayed neurocognitive recovery.
• Dysregulated CBS/H2S signaling promotes chronic stress-induced colonic hypermotility.
• CBS is a target for pharmacological chaperones like givinostat in homocystinuria.
• CBS X proteins negatively regulate NADPH-thioredoxin reductase C in plants, indicating evolutionary conservation.
• CRISPR models enable precise dissection of CBS function in disease.
What Happens During cystathionine beta-synthase activity?
Substrate Binding and Activation
In simple terms: The enzyme grabs serine and homocysteine and gets ready to join them.
Cystathionine beta-synthase (CBS) binds L-serine and L-homocysteine in its active site, which contains a pyridoxal 5'-phosphate (PLP) cofactor. The enzyme is activated by S-adenosylmethionine (SAM), which binds to the C-terminal regulatory domain and induces conformational changes that enhance catalytic activity. Disease-causing mutations in the linker region between the catalytic and regulatory domains impair this allosteric activation, leading to reduced CBS activity.
Catalytic Condensation
In simple terms: The enzyme chemically links serine and homocysteine to form cystathionine.
The PLP cofactor forms a Schiff base with the amino group of L-serine, facilitating the elimination of water and the formation of an aminoacrylate intermediate. This intermediate then reacts with L-homocysteine to produce cystathionine and regenerate the enzyme. The reaction is a beta-replacement, where the hydroxyl group of serine is replaced by homocysteine.
Product Release and Transsulfuration
In simple terms: Cystathionine is released and further processed to cysteine.
After catalysis, cystathionine is released and subsequently cleaved by cystathionine gamma-lyase to yield cysteine, alpha-ketobutyrate, and ammonia. This completes the transsulfuration pathway, which irreversibly converts homocysteine to cysteine. Cysteine is then used for protein synthesis and glutathione production.
Allosteric Regulation by SAM
In simple terms: SAM acts as a gas pedal, telling the enzyme to work faster.
S-adenosylmethionine (SAM) binds to the C-terminal regulatory domain of CBS, activating the enzyme. This regulation ensures that homocysteine is removed when methionine is abundant. Mutations in the linker region disrupt SAM binding and allosteric activation, contributing to homocystinuria.
Heme Cofactor and Redox Sensitivity
In simple terms: A heme group helps the enzyme respond to its environment.
CBS contains a heme cofactor that is not directly involved in catalysis but may play a structural or regulatory role. The heme is coordinated by cysteine and histidine residues and can sense redox conditions. Mutations affecting heme binding can reduce CBS stability and activity.
Key Genes Involved in GO:0004122 cystathionine beta-synthase activity
The following genes and proteins are directly involved in or regulate cystathionine beta-synthase activity and its associated pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CBS | Encodes cystathionine beta-synthase, the enzyme catalyzing the reaction. | Mutations cause homocystinuria; target for pharmacological chaperones. |
| MTR | Methionine synthase, regenerates methionine from homocysteine. | Linked to methionine cycle and CBS regulation. |
| MTHFR | Methylenetetrahydrofolate reductase, provides methyl groups for homocysteine remethylation. | Polymorphisms affect homocysteine levels and CBS flux. |
| CTH | Cystathionine gamma-lyase, converts cystathionine to cysteine. | Second step of transsulfuration; potential drug target. |
| MAT1A | Methionine adenosyltransferase, synthesizes SAM. | Regulates SAM levels and CBS allosteric activation. |
| AHCY | S-adenosylhomocysteine hydrolase, hydrolyzes SAH to homocysteine. | Influences homocysteine availability for CBS. |
| CBSX1 | Cystathionine-beta-synthase X protein 1, regulates NTRC in plants. | Model for CBS domain function in redox regulation. |
| CBSX2 | Cystathionine-beta-synthase X protein 2, regulates NTRC in plants. | Model for CBS domain function in redox regulation. |
| NTRC | NADPH-thioredoxin reductase C, target of CBSX proteins. | Studied for redox regulation and CBS domain interactions. |
| GIVINOSTAT | Histone deacetylase inhibitor, rescues CBS folding. | Therapeutic candidate for homocystinuria. |
| ISOFURANE | Inhibits CBS, contributing to neurocognitive recovery. | Anesthetic effects on CBS activity. |
| H2S | Hydrogen sulfide, product of CBS alternative activity. | Signaling molecule in colonic motility. |
| PLP | Pyridoxal 5'-phosphate, essential cofactor for CBS. | Cofactor supplementation in CBS deficiency. |
| SAM | S-adenosylmethionine, allosteric activator of CBS. | Regulates CBS activity in response to methionine. |
| HOMOCYSTEINE | Substrate of CBS, elevated in homocystinuria. | Biomarker for CBS deficiency. |
| SERINE | Substrate of CBS, provides carbon skeleton for cystathionine. | Metabolic precursor in transsulfuration. |
| CYSTATHIONINE | Product of CBS reaction, intermediate in cysteine synthesis. | Measured to assess CBS activity. |
| LEUKEMIA CELL LINES | Express varying levels of CBS. | Model for studying CBS in cancer. |
How Is cystathionine beta-synthase activity Regulated?
Cystathionine beta-synthase activity is regulated at multiple levels. Allosteric activation by S-adenosylmethionine (SAM) is the primary mechanism, where SAM binds to the C-terminal regulatory domain and enhances catalytic activity. Disease-causing mutations in the linker region between catalytic and regulatory domains impair this allosteric regulation, leading to reduced CBS function. Additionally, CBS expression can be influenced by cellular redox status and heme availability. In cancer cells, CBS expression varies and may be subject to epigenetic regulation. Pharmacological chaperones like givinostat can rescue folding and activity of mutant CBS, indicating that protein folding and stability are key regulatory nodes.
cystathionine beta-synthase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CBS | Classical homocystinuria | CBS knockout mice, patient-derived fibroblasts, CRISPR point-mutation models |
| CBS | Leukemia cell proliferation | Human leukemia cell lines with CBS knockdown or overexpression |
| CBS | Isoflurane-induced neurocognitive recovery | Mouse models with CBS inhibition, behavioral tests |
| CBS | Chronic stress-induced colonic hypermotility | Rat models with CBS/H2S dysregulation |
| CBSX1/CBSX2 | Redox regulation in plants | Arabidopsis mutants, NTRC activity assays |
Classical Homocystinuria
Classical homocystinuria is an autosomal recessive disorder caused by loss-of-function mutations in the CBS gene, leading to deficient cystathionine beta-synthase activity. Patients present with elevated plasma homocysteine, ectopia lentis, skeletal abnormalities, thromboembolism, and intellectual disability. Over 150 mutations in CBS have been identified, including missense, nonsense, and splice-site variants that impair enzyme activity or stability. Newborn screening and early treatment with pyridoxine, betaine, and dietary methionine restriction can reduce complications.
CBS in Cancer
Cystathionine beta-synthase expression and activity are dysregulated in various cancers, including leukemia. Human leukemia cell lines show differential expression of CBS, suggesting a role in cancer cell metabolism and proliferation. CBS contributes to hydrogen sulfide production, which can promote tumor growth and angiogenesis. Targeting CBS activity is being explored as a therapeutic strategy in cancers dependent on transsulfuration.
Neurological and Psychiatric Disorders
CBS activity is critical for brain function, as homocysteine is neurotoxic and hydrogen sulfide acts as a neuromodulator. Inhibition of CBS by isoflurane contributes to delayed neurocognitive recovery after anesthesia in mice. Dysregulated CBS/H2S signaling promotes chronic stress-induced colonic hypermotility in rats, linking CBS to gut-brain axis function. These findings suggest that CBS modulators may have therapeutic potential in neurological and psychiatric conditions.
From cystathionine beta-synthase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of CBS loss on homocysteine metabolism? | CBS knockout cell lines or mice |
| How do specific CBS mutations affect enzyme activity? | CRISPR point-mutation knock-in cell lines |
| Can pharmacological chaperones rescue mutant CBS? | Patient-derived cells or knock-in models treated with givinostat |
| What is the role of CBS in cancer cell proliferation? | CBS overexpression or knockout in leukemia cell lines |
| How does CBS inhibition affect neuronal function? | CBS knockout mice or isoflurane-treated models |
| What is the impact of CBS on colonic motility? | CBS knockout rats or H2S signaling models |
How to Study the cystathionine beta-synthase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic activity assay | Cystathionine production from serine and homocysteine | Assessing CBS activity in cell lysates |
| Western blot | CBS protein expression and stability | Comparing CBS levels across cell lines |
| CRISPR-Cas9 knockout | Loss of CBS function | Generating CBS-null cells for metabolic studies |
| CRISPR point mutation | Effect of specific CBS variants | Modeling homocystinuria mutations |
| Metabolomics | Homocysteine, cystathionine, cysteine levels | Diagnosing CBS deficiency and monitoring treatment |
| H2S measurement | Hydrogen sulfide production | Studying CBS signaling in colon motility |
| Pharmacological chaperone assay | Rescue of mutant CBS folding | Testing givinostat and other compounds |
| Animal behavioral tests | Neurocognitive function | Evaluating effects of CBS inhibition |
Enzymatic Activity Assays
Cystathionine beta-synthase activity can be measured using spectrophotometric or HPLC-based assays that detect cystathionine formation from serine and homocysteine. These assays are used to assess the impact of mutations, pharmacological chaperones, or inhibitors on CBS function.
Western Blotting and Immunodetection
Western blotting with CBS-specific antibodies is used to quantify CBS protein levels in cells and tissues. This method helps determine whether changes in activity are due to altered expression or stability.
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 is used to generate CBS knockout, point-mutation, and knock-in cell models to study the functional consequences of specific genetic variants. These models enable precise dissection of CBS structure-function relationships and disease mechanisms.
Metabolomics and Homocysteine Quantification
Metabolomic profiling, including measurement of homocysteine, cystathionine, and cysteine, is used to assess CBS activity in cells and animal models. Elevated homocysteine is a biomarker of CBS deficiency.
How CRISPR Can Be Used to Study GO:0004122 cystathionine beta-synthase activity
Knockout
CRISPR-Cas9 knockout of CBS is used to create cell and animal models of homocystinuria, enabling studies of homocysteine accumulation and transsulfuration pathway flux. CBS knockout cells show reduced cystathionine production and increased homocysteine, mimicking the human disease.
Point Mutation
CRISPR point-mutation knock-in models introduce specific disease-causing CBS mutations, such as those in the linker region, to study their effects on allosteric regulation and enzyme activity. These models help dissect genotype-phenotype relationships in homocystinuria.
Knock-in
Knock-in of tagged CBS (e.g., GFP or FLAG) allows real-time tracking of CBS localization, stability, and interactions in live cells. This approach is valuable for studying the rescue of mutant CBS by pharmacological chaperones.
Overexpression
CRISPR activation or lentiviral overexpression of CBS is used to study the effects of increased CBS activity on cancer cell proliferation, redox balance, and hydrogen sulfide signaling. Overexpression models help identify downstream pathways modulated by CBS.
How EDITGENE Supports cystathionine beta-synthase activity Research
Researchers studying cystathionine beta-synthase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation of CBS and related genes.
Contact EDITGENE today to design your custom CRISPR model for cystathionine beta-synthase activity research.
Frequently Asked Questions About cystathionine beta-synthase activity
What is cystathionine beta-synthase activity?
Cystathionine beta-synthase activity (GO:0004122) is the enzymatic catalysis of L-serine and L-homocysteine to cystathionine and water, a key step in the transsulfuration pathway.
What genes are involved in cystathionine beta-synthase activity?
The primary gene is CBS, which encodes the enzyme. Other related genes include MTR, MTHFR, CTH, MAT1A, and AHCY, which influence homocysteine and methionine metabolism.
What diseases are associated with cystathionine beta-synthase deficiency?
Deficiency causes classical homocystinuria, characterized by elevated homocysteine, ocular and skeletal abnormalities, and thromboembolism.
How is cystathionine beta-synthase activity regulated?
It is allosterically activated by S-adenosylmethionine (SAM) and requires pyridoxal 5'-phosphate (PLP) and heme cofactors.
What are the symptoms of homocystinuria?
Symptoms include ectopia lentis, osteoporosis, thromboembolism, and intellectual disability due to CBS deficiency.
Can cystathionine beta-synthase activity be measured in the lab?
Yes, enzymatic assays detect cystathionine production from serine and homocysteine, and metabolomics can quantify homocysteine levels.
What is the role of CBS in cancer?
CBS expression is dysregulated in leukemia and other cancers, contributing to hydrogen sulfide production and tumor growth.
How do CRISPR models help study CBS function?
CRISPR knockout, point mutation, and knock-in models allow precise dissection of CBS variants and their effects on enzyme activity and disease.
What is the link between CBS and neurological disorders?
CBS inhibition by isoflurane impairs neurocognitive recovery, and dysregulated CBS/H2S signaling affects colonic motility, suggesting roles in neurological and gut-brain axis disorders.
Are there treatments for CBS deficiency?
Treatment includes pyridoxine, betaine, dietary methionine restriction, and emerging pharmacological chaperones like givinostat.
Conclusion
Cystathionine beta-synthase activity (GO:0004122) is a fundamental molecular function in sulfur amino acid metabolism, catalyzing the conversion of homocysteine to cystathionine. Its dysfunction causes classical homocystinuria, and its dysregulation is implicated in cancer and neurological disorders. Understanding the enzyme's mechanism, regulation, and genetic variants is essential for developing targeted therapies. EDITGENE's CRISPR services provide powerful tools to model CBS-related diseases and accelerate drug discovery.
References
- 1. Roman JV et al.. 2023. Disease-causing cystathionine β-synthase linker mutations impair allosteric regulation.. J Biol Chem 299(12):105449 PMID: 37949228
- 2. Jurkowska H et al.. 2022. Sulfurtransferases and Cystathionine Beta-Synthase Expression in Different Human Leukemia Cell Lines.. Biomolecules 12(2) PMID: 35204649
- 3. Petrosino M et al.. 2025. Givinostat rescues folding of cystathionine beta-synthase and ameliorates murine homocystinuria.. Biochem Pharmacol 239:117079 PMID: 40571220
- 4. Tran CM et al.. 2023. Cystathionine-β-synthase X proteins negatively regulate NADPH-thioredoxin reductase C activity.. Biochem Biophys Res Commun 653:47-52 PMID: 36857899
- 5. Bublil EM et al.. 2020. Classical homocystinuria: From cystathionine beta-synthase deficiency to novel enzyme therapies.. Biochimie 173:48-56 PMID: 31857119
- 6. Xu F et al.. 2025. Direct inhibition of cystathionine-β-synthase by isoflurane contributes to delayed neurocognitive recovery after isoflurane general anaesthesia in mice.. Br J Anaesth 135(2):360-374 PMID: 40483182
- 7. Lin M et al.. 2023. Dysregulated cystathionine-β-synthase/hydrogen sulfide signaling promotes chronic stress-induced colonic hypermotility in rats.. Neurogastroenterol Motil 35(2):e14488 PMID: 36371703
- 8. Kraus JP et al.. 1999. Cystathionine beta-synthase mutations in homocystinuria.. Hum Mutat 13(5):362-75 PMID: 10338090
